专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US08765152B2 Pharmaceutical or neutraceutical formulation 有权
标题翻译：药物或中性制剂
公开(公告)号：US08765152B2
公开(公告)日：2014-07-01
申请号：US13580033
申请日：2010-02-25
申请人： Rosario Lizio , Michael Gottschalk , Michael Damm , Norbert Windhab , Melanie Liefke , Guenter Schmitt , Erna Roth , Ruediger Alexowsky
发明人： Rosario Lizio , Michael Gottschalk , Michael Damm , Norbert Windhab , Melanie Liefke , Guenter Schmitt , Erna Roth , Ruediger Alexowsky
IPC分类号： A61K9/00 , A61K9/16 , A61K38/00 , A61K38/11 , A61K48/00 , A61K31/70 , A61K31/727
CPC分类号： A61K9/1676 , A61K9/5026 , A61K9/5042 , A61K9/5078 , A61K31/727 , A61K38/11 , A61K38/168
摘要： The invention relates to a pharmaceutical or nutraceutical formulation comprising a core, comprising an active pharmaceutical or nutraceutical ingredient, a penetration promoter and a bioavailability promoting agent, and a polymeric coating for the gastrointestinal targeted release of the active ingredient, characterized in that the bioavailability promoting agent is a pharmaceutically acceptable inhibitor of proteolytic enzymes, which increases the oral bioavailability of the active ingredient by a factor of at least five, compared to a corresponding formulation without the bioavailability promoting agent.
摘要翻译：本发明涉及包含核心的药物或营养制剂，其包含活性药物或营养成分，渗透促进剂和生物利用度促进剂，以及用于胃肠靶向释放活性成分的聚合物涂层，其特征在于所述生物利用度促进药剂是药学上可接受的蛋白水解酶抑制剂，与没有生物利用度促进剂的相应制剂相比，其将活性成分的口服生物利用度提高至少5倍。

12. 发明申请

US20120315334A1 PHARMACEUTICAL OR NEUTRACEUTICAL FORMULATION 有权
标题翻译：药物或中性制剂
公开(公告)号：US20120315334A1
公开(公告)日：2012-12-13
申请号：US13580033
申请日：2010-02-25
申请人： Rosario Lizio , Michael Gottschalk , Michael Damm , Norbert Windhab , Melanie Liefke , Guenter Schmitt , Erna Roth , Ruediger Alexowsky
发明人： Rosario Lizio , Michael Gottschalk , Michael Damm , Norbert Windhab , Melanie Liefke , Guenter Schmitt , Erna Roth , Ruediger Alexowsky
IPC分类号： A61K9/00 , A61K31/7088 , A61K9/14 , A61K38/11 , A61K31/727 , A61K38/02 , A61K31/715
CPC分类号： A61K9/1676 , A61K9/5026 , A61K9/5042 , A61K9/5078 , A61K31/727 , A61K38/11 , A61K38/168
摘要： The invention relates to a pharmaceutical or nutraceutical formulation comprising a core, comprising an active pharmaceutical or nutraceutical ingredient, a penetration promoter and a bioavailability promoting agent, and a polymeric coating for the gastrointestinal targeted release of the active ingredient, characterized in that the bioavailability promoting agent is a pharmaceutically acceptable inhibitor of proteolytic enzymes, which increases the oral bioavailability of the active ingredient by a factor of at least five, compared to a corresponding formulation without the bioavailability promoting agent.
摘要翻译：本发明涉及包含核心的药物或营养制剂，其包含活性药物或营养成分，渗透促进剂和生物利用度促进剂，以及用于胃肠靶向释放活性成分的聚合物涂层，其特征在于所述生物利用度促进药剂是药学上可接受的蛋白水解酶抑制剂，与没有生物利用度促进剂的相应制剂相比，其将活性成分的口服生物利用度提高至少5倍。

13. 发明申请

US20120143039A1 ORAL DOSAGE FORM, COMPRISING AT LEAST ONE BIOLOGICALLY ACTIVE AGENT, FORMULATION AUXILIARY SUBSTANCES AND MAGNETIZABLE PARTICLES 有权
标题翻译：口服剂型，包含至少一种生物活性剂，配方辅助物质和可磁化颗粒
公开(公告)号：US20120143039A1
公开(公告)日：2012-06-07
申请号：US13390353
申请日：2010-08-30
申请人： Benedikt Hartwig , Norbert Windhab , Melanie Liefke , Juan Tome Alcalde , Michael Damm , Rosario Lizio , Michael Gottschalk , Angela Olf , Christian Meier , Andreas Gryczke
发明人： Benedikt Hartwig , Norbert Windhab , Melanie Liefke , Juan Tome Alcalde , Michael Damm , Rosario Lizio , Michael Gottschalk , Angela Olf , Christian Meier , Andreas Gryczke
IPC分类号： A61B5/05 , A61J3/07
CPC分类号： A61K9/2072 , A61K9/0009 , A61K9/0053 , A61K9/2095 , A61K9/2813 , A61K9/2846 , A61K9/2866 , A61K9/4808 , A61K9/4816 , A61K9/4833 , A61K9/4883 , A61K9/5094
摘要： The invention relates to an oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles, wherein the dosage form has an at least two phase composition, wherein the phases can dissolve in the body after oral administration due to their formulation and the magnetizable particles are bound in formulation auxiliary substances and are present in a magnetized state, wherein the magnetized particles are present in at least two phases of the dosage form and generate magnetic fields, wherein these phases dissolve at different times in the body after oral administration, and wherein the magnetic field strength with respect to time, position and movement in the body is acquired using a detection system and can be evaluated using a computer-based evaluation system.
摘要翻译：本发明涉及口服剂型，其包含至少一种生物活性剂，制剂辅助物质和可磁化颗粒，其中所述剂型具有至少两相组合物，其中所述相可以在口服给药后溶于体内，因为它们制剂和可磁化颗粒结合在制剂辅助物质中并以磁化状态存在，其中磁化颗粒存在于剂型的至少两个相中并产生磁场，其中这些相在体内不同时间溶解在体内并且其中使用检测系统获取相对于身体中的时间，位置和运动的磁场强度，并且可以使用基于计算机的评估系统进行评估。

14. 发明授权

US09050256B2 Oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles 有权
标题翻译：口服剂型，包含至少一种生物活性剂，制剂辅助物质和可磁化颗粒
公开(公告)号：US09050256B2
公开(公告)日：2015-06-09
申请号：US13390353
申请日：2010-08-30
申请人： Benedikt Hartwig , Norbert Windhab , Melanie Liefke , Juan Tome Alcalde , Michael Damm , Rosario Lizio , Michael Gottschalk , Angela Olf , Christian Meier , Andreas Gryczke
发明人： Benedikt Hartwig , Norbert Windhab , Melanie Liefke , Juan Tome Alcalde , Michael Damm , Rosario Lizio , Michael Gottschalk , Angela Olf , Christian Meier , Andreas Gryczke
IPC分类号： A61B5/055 , A61K9/20 , A61K9/28 , A61K9/48 , A61K9/50 , A61K9/00
CPC分类号： A61K9/2072 , A61K9/0009 , A61K9/0053 , A61K9/2095 , A61K9/2813 , A61K9/2846 , A61K9/2866 , A61K9/4808 , A61K9/4816 , A61K9/4833 , A61K9/4883 , A61K9/5094
摘要： The invention relates to an oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles, wherein the dosage form has an at least two phase composition, wherein the phases can dissolve in the body after oral administration due to their formulation and the magnetizable particles are bound in formulation auxiliary substances and are present in a magnetized state, wherein the magnetized particles are present in at least two phases of the dosage form and generate magnetic fields, wherein these phases dissolve at different times in the body after oral administration, and wherein the magnetic field strength with respect to time, position and movement in the body is acquired using a detection system and can be evaluated using a computer-based evaluation system.
摘要翻译：本发明涉及口服剂型，其包含至少一种生物活性剂，制剂辅助物质和可磁化颗粒，其中所述剂型具有至少两相组合物，其中所述相可以在口服给药后溶于体内，因为它们制剂和可磁化颗粒结合在制剂辅助物质中并以磁化状态存在，其中磁化颗粒存在于剂型的至少两个相中并产生磁场，其中这些相在体内不同时间溶解在体内并且其中使用检测系统获取相对于身体中的时间，位置和运动的磁场强度，并且可以使用基于计算机的评估系统进行评估。

15. 发明申请

US20050014677A1 Solid peptide preparations for inhalation and their preparation 审中-公开
标题翻译：用于吸入及其制备的固体肽制剂
公开(公告)号：US20050014677A1
公开(公告)日：2005-01-20
申请号：US10808239
申请日：2004-03-23
申请人： Rosario Lizio , Michael Damm , Werner Sarlikiotis , Elisabeth Wolf-Heuss
发明人： Rosario Lizio , Michael Damm , Werner Sarlikiotis , Elisabeth Wolf-Heuss
IPC分类号： A61K9/00 , A61K9/14 , A61K9/72 , A61K38/28 , A61K38/00
CPC分类号： A61K9/0075 , A61K9/008 , A61K9/14
摘要： The invention relates to solid pharmaceutical preparations, in particular for inhalatory administration in mammals, their preparation and their use such as, for example, in powder inhalers.
摘要翻译：本发明涉及固体药物制剂，特别是用于哺乳动物的吸入给药，其制备及其用途，例如粉剂吸入器。

16. 发明申请

US20090142407A1 Solid peptide preparations for inhalation and their preparation 审中-公开
公开(公告)号：US20090142407A1
公开(公告)日：2009-06-04
申请号：US12156800
申请日：2008-06-04
申请人： Rosario Lizio , Michael Damm , Werner Sarlikiotis , Elisabeth Wolf-Heuss
发明人： Rosario Lizio , Michael Damm , Werner Sarlikiotis , Elisabeth Wolf-Heuss
IPC分类号： A61K9/14 , A61K38/28
CPC分类号： A61K9/0075 , A61K9/008 , A61K9/14
摘要： The invention relates to solid pharmaceutical preparations, in particular for inhalatory administration in mammals, their preparation and their use such as, for example, in powder inhalers.

17. 发明申请

US20120158969A1 Selective Proxying In Domain Name Systems 有权
标题翻译：域名系统中的选择性代理
公开(公告)号：US20120158969A1
公开(公告)日：2012-06-21
申请号：US13279075
申请日：2011-10-21
申请人： Matthew Dempsky , David Ulevitch , Noah Treuhaft , Michael Damm
发明人： Matthew Dempsky , David Ulevitch , Noah Treuhaft , Michael Damm
IPC分类号： G06F15/173
CPC分类号： H04L61/1511 , H04L61/6013
摘要： Systems and methods for processing requests for domain name information in accordance with subscriber information are provided. A request for domain name information can be correlated with subscriber preferences to resolve the domain name information. Domain names may be flagged for blocking or proxying by one or more subscriber preferences. In response to a flagged domain name, a client device can be redirected to a web server that can function as proxy on behalf of the user for accessing the flagged domain. In one example, user preferences and/or network preferences can be used to determine whether a particular user can bypass a blocking preference and access the flagged domain using the proxy.
摘要翻译：提供了根据用户信息处理域名信息请求的系统和方法。对域名信息的请求可以与用户偏好相关联，以解决域名信息。可以通过一个或多个订阅者偏好来标记域名以阻止或代理。响应于已标记的域名，可以将客户端设备重定向到可以代表用户作为代理的Web服务器，以访问被标记的域。在一个示例中，可以使用用户偏好和/或网络偏好来确定特定用户是否可以绕过阻止偏好并且使用代理来访问被标记的域。

18. 发明申请

US20050159335A1 Pharmaceutical administration form for peptides, process for its preparation, and use 失效
标题翻译：肽的药物管理形式，其制备方法和用途
公开(公告)号：US20050159335A1
公开(公告)日：2005-07-21
申请号：US11028875
申请日：2005-01-04
申请人： Horst Bauer , Michael Damm , Werner Sarlikiotis
发明人： Horst Bauer , Michael Damm , Werner Sarlikiotis
IPC分类号： A61K9/00 , A61K9/08 , A61K9/10 , A61K9/14 , A61K9/19 , A61K38/00 , A61K47/04 , A61K47/12 , A61K47/16 , A61K47/18 , A61K47/22 , A61K47/24 , A61K47/26 , A61K47/30 , A61K47/32 , A61K47/34 , A61K47/38 , A61K47/40 , A61K47/42 , A61K47/44 , A61P5/24 , A61P13/08 , A61P15/00 , A61P17/00 , A61P35/00 , A61K38/17
CPC分类号： A61K47/40 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K47/12 , A61K47/26 , Y10S514/80
摘要： A method for preventing aggregation of an LHRH antagonist in a pharmaceutical composition. The method comprises combining the LHRH antagonist in the form of an acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salt at least one of the acids for forming the salts in free acid form.
摘要翻译：一种用于预防药物组合物中LHRH拮抗剂聚集的方法。该方法包括将乙酸盐，葡萄糖酸盐，葡萄糖醛酸盐，乳酸盐，柠檬酸盐，抗坏血酸盐，苯甲酸盐或磷酸盐形式的LHRH拮抗剂组合成形成游离酸形式的盐的至少一种酸。

19. 发明授权

US08676989B2 Robust domain name resolution 有权
标题翻译：强大的域名解析
公开(公告)号：US08676989B2
公开(公告)日：2014-03-18
申请号：US12723447
申请日：2010-03-12
申请人： Noah Treuhaft , David Ulevitch , Michael Damm
发明人： Noah Treuhaft , David Ulevitch , Michael Damm
IPC分类号： G06F15/16
CPC分类号： H04L61/1511 , H04L29/12066 , H04L29/12811 , H04L61/3025 , H04L61/35 , H04L61/6009
摘要： A recursive DNS nameserver system and related domain name resolution techniques are disclosed. The DNS nameservers utilize a local cache having previously retrieved domain name resolution to avoid recursive resolution processes and the attendant DNS requests. If a matching record is found with a valid (not expired) TTL field, the nameserver returns the cached domain name information to the client. If the TTL for the record in the cache has expired and the nameserver is unable to resolve the domain name information using DNS requests to authoritative servers, the recursive DNS nameserver returns to the cache and accesses the resource record having an expired TTL. The nameserver generates a DNS response to the client device that includes the domain name information from the cached resource record. In various embodiments, subscriber information is utilized to resolve the requested domain name information in accordance with user-defined preferences.
摘要翻译：公开了递归的DNS名称服务器系统和相关的域名解析技术。 DNS名称服务器利用具有先前检索到的域名解析的本地缓存来避免递归解决过程和伴随的DNS请求。如果找到具有有效（未过期）TTL字段的匹配记录，则名称服务器将缓存的域名信息返回给客户端。如果缓存中的记录的TTL已经过期，并且名称服务器无法使用向权威服务器的DNS请求来解析域名信息，则递归DNS名称服务器返回到缓存并访问具有过期的TTL的资源记录。名称服务器将生成DNS客户端设备的DNS响应，其中包括缓存的资源记录中的域名信息。在各种实施例中，用户信息用于根据用户定义的偏好来解析所请求的域名信息。

20. 发明申请

US20130275570A1 Cross-Protocol Communication In Domain Name Systems 有权
公开(公告)号：US20130275570A1
公开(公告)日：2013-10-17
申请号：US13448368
申请日：2012-04-16
申请人： Noah Treuhaft , Douglas Tabacco , Michael Damm
发明人： Noah Treuhaft , Douglas Tabacco , Michael Damm
IPC分类号： G06F15/173
CPC分类号： H04L61/1511 , H04L61/303 , H04L67/10
摘要： Systems and methods for processing domain name system requests in accordance with subscriber information are provided. A request for domain name information can be correlated with subscriber information using a subscriber identifier to resolve the domain name information at a domain name system (DNS) nameserver. The subscriber identifier and/or subscriber information may be transmitted from a DNS nameserver to a webserver using the domain name information provided in response to the subscriber's DNS queries. The subscriber identifier and/or information may be used in delivering a landing page or in facilitating proxying of resource requests for the requested domain.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式